|
SEER SINQ Updates
Follow this link to a listing of SEER SINQ's that have been finalized during the months of August thru December 2023.
Highlights of this listing include:
-
20230040 informs whether Lupron is coded as first course therapy in a patient who initially elected active surveillance for prostate cancer and then consented to treatment with Lupron.
-
20230037 instructs if intracholecystic papillary-tubular neoplasm (IPCN) with extensive high-grade dysplasia of the gallbladder is reportable.
-
20230034 shares how to properly code Melanoma Surgery Codes and Date of First Surgical Procedure for punch biopsy, NOS and shave biopsy, NOS since significant changes were made in 2023.
Click here to access the SEER SINQ Website.
| 
